Dapagliflozin significantly reduced the HbA1c level and FBG of type 2 diabetes patients as add-on therapy, regardless of the type of the coadministered OHA or insulin within a 6-month treatment period. The gene discussed is INS; the disease is type 2 diabetes mellitus.